Bank Of New York Mellon Corp Gt Biopharma, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.46 - $1.05 $43,809 - $100,000	95,239 New	95,239 $52.4 Million
Q4 2022 Feb 14, 2023	BUY	$0.89 - $58.2 $84,762 - $5.54 Million	95,239 New	95,239 $84,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $6,199 - $192,142	-3,425 Reduced 3.47%	95,239 $167,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $71,149 - $134,924	-43,384 Reduced 30.54%	98,664 $294,000
Q1 2022 May 11, 2022	SELL	$2.6 - $3.3 $7,995 - $10,147	-3,075 Reduced 2.12%	142,048 $409,000
Q4 2021 Feb 11, 2022	BUY	$3.05 - $7.08 $24,299 - $56,406	7,967 Added 5.81%	145,123 $441,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $15.26 $524,012 - $1.2 Million	78,445 Added 133.61%	137,156 $925,000
Q2 2021 Aug 11, 2021	BUY	$7.19 - $18.96 $422,132 - $1.11 Million	58,711 New	58,711 $910,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.